Search

Zaverio M Ruggeri

from San Diego, CA
Age ~79
Get Report
Also known as:
Zaverio Rosamaria Ruggeri
Related to:
Rosamaria Carrara Ruggeri, 77
Connected to:
Ann K Ruggeri, 94Ashlee N Ruggeri, 37Edward Ruggerio, 34Erica J Ruggeri, 45Gina M Ruggerio, 39Jami Ruggeri, 34Jorge L Ruggeri, 53Marianna A Ruggerio, 36Nicole Ruggeri, 48Rachel G Ruggeri, 40

Zaverio Ruggeri Phones & Addresses

  • San Diego, CA
  • 6633 Avenida De Las Pescas, La Jolla, CA 92037 (858) 459-2189
  • 644 Bonair St, La Jolla, CA 92037 (858) 454-1709

Work

Position: Market researcher

Industries

Biotechnology

Resumes

Resumes

Zaverio Ruggeri Photo 1

Market Researcher

View page
Location:
La Jolla, CA
Industry:
Biotechnology
Work:

Market Researcher

Business Records

Name / Title
Company / Classification
Phones & Addresses
Zaverio M. Ruggeri
Director
NORTH AMERICAN SOCIETY ON THROMBOSIS AND HEMOSTASIS, INC
11 Beacon St SUITE 800 - ATTN: WILLIAM M MANDELL, Boston, MA 02108
Scripps Ri, La Jolla, CA 92037

Publications

Us Patents

Platelet Binding Inhibitors

View page
US Patent:
46832912, Jul 28, 1987
Filed:
Oct 28, 1985
Appl. No.:
6/791872
Inventors:
Theodore S. Zimmerman - La Jolla CA
Zaverio M. Ruggeri - La Jolla CA
Richard Houghten - Solhna Beach CA
Assignee:
Scripps Clinic and Research Foundation - La Jolla CA
International Classification:
A61K 3702
C07C10352
US Classification:
530324
Abstract:
Peptides of the general formula H. sub. 2 N-(Ch)-Arg-Gly-Asp-(Cx)-H and the derivatives thereof described herein, wherein (Cx) and (Ch) each contains 1 to 20 amino acid residues and (Ch) contains at least one Lys or Arg residue, or at least one of each, inhibit platelet-fibrinogen binding and platelet-platelet aggregation and are thus useful inhibitors of cell adhesion.

Expression Vectors Encoding Alloantigens Of Glycoprotein Ib.alpha.

View page
US Patent:
54279399, Jun 27, 1995
Filed:
Jan 6, 1992
Appl. No.:
7/817852
Inventors:
Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C12N 121
C12N 510
C12N 1512
C12N 1563
US Classification:
4352402
Abstract:
A method of inhibiting platelet transfusion refractoriness comprising administering third-party platelets to a patient whose platelet glycoprotein Ib. alpha. polypeptides expressed from the patient's DNA have been determined to have either threonine or methionine residues, or both, at amino acid residue position 145 thereof, said third-party platelets having expressed at residue position 145 of the glycoprotein Ib. alpha. polypeptide thereof amino acids that are the same as those expressed on the glycoprotein Ib. alpha. polypeptides of the patient's platelets. Also, an antibody, or a fragment thereof, in substantially pure form having as its target epitope a domain of glycoprotein Ib. alpha. , the affinity of said antibody, or fragment thereof, for said epitope being dependent on the identity of the amino acid residue at position 145 of said glycoprotein. In addition, in a process for storing a supply of platelets for therapeutic use in a patient, the improvement comprising segregating said platelets into three stocks dependent upon whether residue 145 of glycoprotein Ib. alpha.

Gpib.alpha. Fragments And Recombinant Dna Expression Vectors

View page
US Patent:
53407270, Aug 23, 1994
Filed:
Nov 14, 1990
Appl. No.:
7/613083
Inventors:
Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C12N 1512
C12N 1585
A61K 3702
US Classification:
435 696
Abstract:
Recombinant DNA expression vectors encoding a peptide which inhibits binding of von Willebrand factor to platelet membrane glycoprotein Ib, said vector including a nucleotide sequence encoding the amino acid sequence from HIS. sup. 1 to LEU. sup. 610, inclusive, of the amino terminal region of platelet membrane glycoprotein Ib. alpha. , or any sequential subset thereof; mammalian host cells transformed by said vectors; and a process for producing a peptide having the identifying characteristics of the 45 kDa tryptic fragment of glycocalicin comprising the steps of (A) providing a stable, extrachromosomally replicable vector capable of directing in mammalian cells the expression of a nucleotide sequence encoding an amino acid sequence which includes said fragment, said nucleotide sequence further encoding as part of said amino acid sequence amino acids which are not native to said fragment, and which are oriented at the carboxy terminus of said fragment, (B) transforming said mammalian cells with said vector, and (C) maintaining said transformed mammalian cells under conditions permitting the expression of said peptide.

Peptides That Inhibit Von Willebrand Factor Binding To The Platelet Spib Receptor

View page
US Patent:
52389197, Aug 24, 1993
Filed:
May 7, 1990
Appl. No.:
7/519606
Inventors:
Theodore S. Zimmerman - La Jolla CA
Yoshihiro Fujimura - Kashihara, JP
Richard A. Houghten - Solana Beach CA
Zaverio M. Ruggeri - La Jolla CA
Assignee:
Scipps Clinic and Research Foundation - La Jolla CA
International Classification:
A61K 3516
A61K 3702
C07K 408
C07K 1514
US Classification:
514 8
Abstract:
This invention provides a peptide fragment of human von Willebrand Factor (vWF) and sub-fragment thereof isolated as enzymtic digestion products from naturally occurring human vWF, or isolated from synthetic peptide mixtures or isolated from lysates of organisms capable of producing recombinant human vWF. The fragments and sub-fragments are useful in the prevention and treatment of cardiovascular disorders by virtue of their ability to inhibit the binding of vWF to platelets, heparin and/or collagen.

Antibodies And Immunoassays For Detecting Platelet Transfusion Refractoriness

View page
US Patent:
57982163, Aug 25, 1998
Filed:
Jun 6, 1995
Appl. No.:
8/470137
Inventors:
Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
G01N 33567
G01N 33537
US Classification:
435 721
Abstract:
A method of inhibiting platelet transfusion refractoriness comprising administering third-party platelets to a patient whose platelet glycoprotein Ib. alpha. polypeptides expressed from the patient's DNA have been determined to have either threonine or methionine residues, or both, at amino acid residue position 145 thereof, the third-party platelets having expressed at residue position 145 of the glycoprotein Ib. alpha. polypeptide thereof amino acids that are the same as those expressed on the glycoprotein Ib. alpha. polypeptides of the patient's platelets. Also, an antibody, or a fragment thereof, in substantially pure form having as its target epitope a domain of glycoprotein Ib. alpha. , the affinity of the antibody, or fragment thereof, for said epitope being dependent on the identity of the amino acid residue at position 145 of the glycoprotein. In addition, in a process for storing a supply of platelets for therapeutic use in a patient, the improvement comprising segregating the platelets into three stocks dependent upon whether residue 145 of glycoprotein Ib. alpha.

Therapeutic Domains Of Van Willebrand Factor

View page
US Patent:
59004762, May 4, 1999
Filed:
Feb 26, 1992
Appl. No.:
7/841591
Inventors:
Zaverio M. Ruggeri - La Jolla CA
Jerry L. Ware - Encinitas CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07K 14745
C12N 1512
A61K 3836
US Classification:
530380
Abstract:
A polypeptide which is capable of inhibiting binding of von Willebrand factor (vWF) to platelets and comprising an amino acid sequence that corresponds to the amino acid sequence of that fragment of mature von Willebrand factor subunit having its amino terminus at about Cys. sup. 509 and its carboxy terminus at about Cys. sup. 695, said polypeptide comprising optionally a second and/or a third domain, the second domain corresponding to the amino acid sequence of that fragment of mature vWF subunit having its amino terminus at about Thr. sup. 450 and its carboxy terminus at about Tyr. sup. 508, or a subfragment or combination of subfragments thereof, and a third domain corresponding to the amino acid sequence of that fragment of mature vWF subunit having its amino terminus at about Asp. sup. 696 and its carboxy terminus at about Gly. sup. 727, or a subfragment or combination of subfragments thereof; and also a process for producing said polypeptides from encoding DNA sequences, and also a method of inhibiting or treating thrombosis in a patient which comprising administering to such patient an effective amount of a therapeutic composition comprising one or more polypeptides of the invention.
Control profile
Zaverio M Ruggeri from San Diego, CA, age ~79 Get Report